Biocon may list biosimilars business by 2025 first half – CEO
By Rishika Sadam HYDERABAD (Reuters) – Indian biopharmaceutical company Biocon Ltd is planning to list its biosimilars business, a significant contributor to the company’s total revenue, by the first half of 2025, a top executive said on Friday. Biocon Biologics, a fully integrated subsidiary of Biocon Ltd, focuses on making biosimilars, with key revenue-generating markets …
Biocon may list biosimilars business by 2025 first half – CEO Read More »





